RORC and Familial prostate cancer: RORγ drives AR expression while selective RORγ antagonists inhibit AR expression and prostate tumor growth (Figure 1) [49,50], suggesting an oncogenic role for RORγ and its potential as a therapeutic target in prostate cancer.